Mandate

Bravida listed on Nasdaq Stockholm

October 22, 2015

Bravida Holding AB (publ) has on 16 October 2015 been admitted to trading on Nasdaq Stockholm. The price in the offering was set at SEK 40 per share, corresponding to a market value of all shares issued by Bravida of SEK 8.1 billion. The offer, which consisted of an offer to the general public in Sweden and an international offer to institutional investors, comprised in total 40.5 percent of the Bravida shares offered by Bravissima Holding AB, Bravida´s principal owner, which is indirectly controlled by certain investment funds advised by Bain Capital, LLC and affiliated parties. The total value of the offering amounts to SEK 3.2 billion, assuming that the over-allotment option is exercised in full.

Bravida is a leading provider of multi-technical services within electricity, heating and plumbing as well as ventilation and air conditioning in the Nordic region. With 237 branches across 140 locations, Bravida offers installation and services solutions throughout the Nordic region with strong local presence. For the year ended 31 December 2014, Bravida recorded net sales of SEK 12 billion.

Bravida and Bravissima Holding AB were advised by Vinge in connection with the listing and Vinge’s team mainly consisted of Charlotte Levin, Christina Kokko, Louise Brorsson Salomon, Nicolina Kindblom, Rikard Lindahl, Nils Fredrik Dehlin, Emelie Klefbeck, Filip Öhrner, Linn Adelwald and Samra Baytar. Further, Odile Fallenius, Maria Schultzberg and Tora Hansjons have assisted with tax related matters.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025